DIOVAN TABLET 160 MG [SIN11554P]

Product Info

DIOVAN TABLET 160 MG

[SIN11554P]

INDICATIONS

Hypertension

Treatment of hypertension.

Heart failure

Treatment of heart failure (NYHA class II–IV) in patients receiving standard therapy such as diuretics, digitalis and either angiotensin-converting enzyme (ACE) inhibitors or beta- blockers but not both; presence of all these standard therapies is not mandatory.

Diovan improves morbidity in these patients, primarily via reduction in hospitalization for heart failure. Diovan also slows the progression of heart failure, improves NYHA functional class, ejection fraction and signs and symptoms of heart failure and improves quality of life versus placebo (see section CLINICAL PHARMACOLOGY – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Post-myocardial infarction

Diovan is indicated to improve survival following recent myocardial infarction in clinically stable patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see section CLINICAL PHARMACOLOGY – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

DOSAGE REGIMEN AND ADMINISTRATION

Dosage regimen
Hypertension

The recommended dose of Diovan is 80 mg once daily, irrespective of race, age, or gender. The maximum antihypertensive effect is seen after 4 weeks. In patients whose blood pressure is not adequately controlled, the daily dose may be increased to 160mg. If additional blood pressure reduction is required, a diuretic may be added or the dose can be increased further to a maximum of 320 mg.

Diovan may also be administered with other antihypertensive agents.

Heart failure

The recommended starting dose of Diovan is 40 mg twice daily. Up-titration to 80 mg and 160 mg twice daily should be done to the highest dose tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses.

Evaluation of patients with heart failure should always include assessment of renal function.

Post-myocardial infarction

Therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan therapy should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet.

Achievement of the target dose of 160mg twice daily should be based on the patient’s tolerability to valsartan during titration. If symptomatic hypotension or renal dysfunction occur, consideration should be given to dosage reduction.

Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers or statins.

Evaluation of post-myocardial infarction patients should always include assessment of renal function.

NOTE for all indications: No dosage adjustment is required for patients with renal impairment or for patients with hepatic impairment of non-biliary origin and without cholestasis.

Use in children and adolescents

The safety and efficacy of Diovan have not been established in children and adolescents (below the age of 18 years).

Method of administration

Film-coated tablets: Diovan may be taken independently of a meal and should be administered with water.

CONTRAINDICATIONS

Severe hepatic impairment, cirrhosis, biliary obstruction

Severe renal impairment (creatinine clearance < 10mL/min) and patients undergoing dialysis.

Known hypersensitivity to valsartan or to any of the excipients of Diovan

Pregnancy (see section PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

Concomitant use of angiotensin receptor antagonists (ARBs) - including Diovan - or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren in patients with Type 2 diabetes (see section INTERACTIONS, subsection Dual blockade of the RAS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

The concomitant use of Diovan with aliskiren-containing products is contraindicated in patients with renal impairment (GFR <60 mL/min/1.73m²) (see INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).